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ABSTRACT
To assess the therapeutic outcome of selective block of VEGFR1, we have 
evaluated the activity of a new specific antagonist of VEGFR1, named iVR1 (inhibitor 
of VEGFR1), in syngenic and xenograft colorectal cancer models, in an artificial model 
of metastatization, and in laser-induced choroid neovascularization. iVR1 inhibited 
tumor growth and neoangiogenesis in both models of colorectal cancer, with an 
extent similar to that of bevacizumab, a monoclonal antibody anti-VEGF-A. It potently 
inhibited VEGFR1 phosphorylation in vivo, determining a strong inhibition of the 
recruitment of monocyte-macrophages and of mural cells as confirmed, in vitro, by the 
ability to inhibit macrophages migration. iVR1 was able to synergize with irinotecan 
determining a shrinkage of tumors that became undetectable after three weeks of 
combined treatment. Such treatment induced a significant prolongation of survival 
similar to that observed with bevacizumab and irinotecan combination. iVR1 also 
fully prevented lung invasion by HCT-116 cells injected in mouse tail vein. Also, iVR1 
impressively inhibited choroid neovascularization after a single intravitreal injection. 
Collectively, data showed the strong potential of iVR1 peptide as a new anti-tumor 
and anti-metastatic agent and demonstrate the high flexibility of VEGFR1 antagonists 
as therapeutic anti-angiogenic agents in different pathological contexts.
INTRODUCTION
The development and maintenance of functional 
vessels through angiogenesis and arteriogenesis processes 
in pathological conditions require the cooperation of 
several growth factor families, of multiple cell types and 
the presence of certain conditions such as hypoxia and 
inflammation [1, 2]. The family of vascular endothelial 
growth factors (VEGF) and related receptors play a central 
role in promoting vessel formation and maturation. Indeed, 
since a decade they are the only validated targets for the 
anti-angiogenesis therapy in cancer and ocular neovascular 
diseases [3, 4]. After the approval by FDA of bevacizumab 
(Avastin), a humanized monoclonal antibody (mAb) 
against VEGF-A for the treatment of metastatic colorectal 
carcinoma (mCRC) in combination with chemotherapy 
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[5], other anti-angiogenic drugs targeting members of 
VEGF family have been developed such as aflibercept, a 
recombinant fusion protein consisting of VEGF-binding 
extracellular domains of VEGFR1 and VEGFR2 fused to 
the Fc portion of human IgG1, and several multitargets 
tyrosine kinase inhibitors which inhibit also VEGF 
receptors [4].
Anti-angiogenic drugs have been approved to 
treat different types of cancer, such as mCRC, non-small 
cell lung carcinoma, metastatic renal cell carcinoma, 
gastrointestinal stromal tumor, hepatocellular carcinoma, 
and others. However, despite the significant clinical 
success of anti-angiogenic therapies, alternative strategies 
are desirable to improve their therapeutic efficacy and to 
overcome inherent/acquired resistance and the relevant 
side effects [6, 7].
VEGF receptor 1 (VEGFR1, also known as Flt-
1) is the common receptor for the three pro-angiogenic 
family members VEGF-A, VEGF-B, and placental growth 
factor (PlGF). It is the unique receptor for VEGF-B and 
PlGF, and shows higher affinity for VEGF-A compared 
to VEGFR-2 (also known as KDR or Flk-1), which is 
exclusively recognized by VEGF-A. VEGFR1 expression 
is upregulated by hypoxia and is also expressed as 
soluble form generated by an alternative splicing (termed 
sVEGFR1), which is one of the most potent physiological 
inhibitor of angiogenesis [8].
Differently from VEGFR2 found almost exclusively 
in endothelial cells, VEGFR1 is expressed in several types 
of cells, many of which play a fundamental role during the 
angiogenesis and arteriogenesis process. Endothelial cells, 
bone marrow stem/precursor cells, circulating endothelial 
cells, stromal cells, perycites and smooth muscle cells, 
monocyte-macrophages, dendritic cells, all express 
functional VEGFR1 that once activated induces mainly 
survival, proliferation and migration pathways [9]. In 
addition, several human cancer cells express VEGFR1 [10].
VEGFR1 was initially classified as decoy receptor 
for VEGF-A because of its low tyrosine kinase activity, 
compared to VEGFR2 [11], and the viability of mice in 
which VEGFR1 tyrosine kinase domain was ablated 
(Flt1tk−/−) [12]. However several other reports re-evaluated 
it as a functional receptor, thereby as possible therapeutic 
target. Flt1tk−/− mice showed impaired angiogenesis 
and reduced inflammation under several disease 
conditions, such as arthritis, atherosclerosis, choroidal 
neovascularization and cancer growth [13–15]. The 
activation of VEGFR1 promotes tumor angiogenesis and 
metastasis through diverse mechanisms [16]. It stimulates 
angiogenesis by recruiting endothelial and monocyte 
progenitor cells from bone marrow into tumor vasculature 
[17, 18] as well as smooth muscle cells to cover and 
stabilize neovessels [19]. VEGFR1 also plays a central role 
in the modulation of inflammatory component of tumors, 
driving the recruitment and activity of macrophages and 
dendritic cells and contributing to tumor-cell survival 
during the epithelial–mesenchymal transition [20]. 
Furthermore, VEGFR1 activation markedly promotes 
pulmonary metastases through induction of matrix 
metalloproteinase-9 secretion [21] and plays a crucial role 
in the establishment of pre-metastatic niches [22].
The functional role of VEGFR1 in tumor and 
metastasis contexts was confirmed using inhibitors from 
different sources. Ribozyme [23], mAb [24], peptides [25, 
26], or DNAzyme [27] specifically targeting VEGFR1, all 
inhibit tumor growth and metastasis formation.
Here, we describe the potent anti-angiogenic, 
anti-tumor, and anti-metastatic activity of a tetrameric 
tripeptide named iVR1 (inhibitor of VEGFR1), which 
is able to specifically bind mouse and human VEGFR1 
blocking receptor activation by preventing the interaction 
of the natural ligands VEGF-A, VEGF-B, PlGF and 
VEGF-A/PlGF heterodimer (IC
50
 6–10 μM) [28].
The anti-angiogenic activity of iVR1 has been first 
assessed in the choroid neovascularization (CNV) model. 
Then, iVR1 activity has been assayed in syngenic and 
xenograft models of colorectal cancer and compared to 
that of mAbs inhibiting the two main ligands of VEGFR1, 
VEGF-A and PlGF. The ability of iVR1 to synergize 
with chemotherapy, as well as the anti-metastatic 
properties, evaluating lung invasion by colorectal cancer 
cells injected in the blood circulation, have been also 
investigated.
RESULTS
Anti-angiogenic in vivo activity of iVR1
iVR1, previously referred as 4.23.5, has a mole-
cular mass of 2362.02 g/mol and is composed by the 
tripeptide H
2
N-D-Glu–L-Cys(Bzl)–L-Cha, where D-Glu 
is D-glutammic acid, L-Cys(Bzl) is L-cysteine-S-benzyl 
and L-Cha is L-cyclohexylalanine, engrafted on a tri-
lysine core (Figure 1A, 1B). The in vitro activity of iVR1 
has been yet fully characterized. The presence of unnatural 
amino acids and the multimeric structure confer high 
resistance to degradation in biological fluids. It specifically 
binds VEGFR1 and does not interfere with VEGFR2 
activity. It prevents both the VEGFR1 phosphorylation 
and the capillary-like tube formation of human primary 
endothelial cells, as well as neovascularization of chicken 
embryo chorioallantoic membrane induced by PlGF or 
VEGF-A [28].
In order to assess the iVR1 anti-angiogenic acti-
vity in vivo, we used the laser-induced CNV model. 
Immediately after the induction of laser damage, single 
intravitreal injections of iVR1, of the control peptide 
(CP) and of anti-mouse VEGF-A polyclonal antibody, 
were performed. After seven days, CNV volume was 
evaluated by immunofluorescence analysis of retinal 
pigment epithelium (RPE) choroid flat mounts. CP 
(50 μg, 21 nmol) was unable to inhibit CNV whereas, 
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as expected, anti-mouse VEGF-A induced a strong 
and significant inhibition compared to vehicle and CP 
(−52.5% in average). iVR1 was able to induce a dose-
dependent inhibition with an impressive reduction of CNV 
(−73.0% in average versus vehicle and CP) at the highest 
concentration delivered (50 μg, 21 nmol) (Figure 1C, 1D).
iVR1 inhibited syngeneic and xenograft 
colorectal cancer growth and neovascularization
Syngenic colon carcinomas were generated in 
Balb/c mice by subcutaneous injection of CT26 cells. 
After six days the treatments with vehicle, anti-mouse 
PlGF monoclonal antibody (mAb) 5D11D4 [29], iVR1 
and the control peptide (CP) started [28]. iVR1-treated 
mice showed a strong and significant reduction of tumor 
growth starting from six days of treatment, compared 
to vehicle and CP, and also compared to mAb 5D11D4, 
which was also able to inhibit tumor growth but with less 
efficacy (Figure 2A). Tumor growth reduction paired with 
inhibition of tumor neoangiogenesis, as assessed by vessel 
density measurement of tumors explanted 16 days after 
cell inoculation. iVR1 and 5D11D4 were able to induce a 
significant and similar inhibition of blood vessel density 
compared to vehicle and CP (−59.8% and −55.3% in 
average, respectively) (Figure 2B).
To generate tumor xenografts, we injected the 
HCT-116 colorectal cancer cells in athymic nude mice 
and, after seven days, treatments with bevacizumab, anti-
human PlGF mAb 16D3, iVR1 and CP peptides started 
(Figure 2C). Surprisingly, tumor growth curves in iVR1 
and bevacizumab treated mice were fully superimposable, 
resulting in a significant tumor growth delay starting from 
four days of treatment, compared to vehicle and CP. The 
mAb 16D3, able to block only PlGF produced by human 
cells, also determined a significant inhibition compared 
to vehicle and CP. Bevacizumab and iVR1 tumor growth 
inhibitions were also significantly higher compared to 
Figure 1: Anti-angiogenic activity of iVR1 in vivo. (A) Chemical structure of iVR1 tetrameric tripeptide that has a calculated 
molecular mass of 2362.02 g/mol. (B) Schematic representation of the iVR1. L-Cys(Bzl): L-cysteine(S-benzyl); L-Cha, L-cyclohexylalanine. 
(C) iVR1 inhibited laser-induced CNV in a dose-dependent manner, whereas CP was ineffective. CNV volumes were measured by confocal 
evaluation of Isolectin B4 staining of RPE-choroid flat mounts. Data are represented as the mean ± SEM (N = 8). *p < 0.0005 and §p < 0.01 
compared to vehicle and CP; #p < 0.05 versus CP. (D) Representative pictures of CNV flat mounts. Scale bar: 100 μm.
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16D3 at the end of treatments (Figure 2C). The analysis 
of vessel density performed on tumors explanted 21 days 
after cell inoculation (Figure 2D, 2E) showed that iVR1 
determined a strong inhibition of neovessel formation 
(−50.7% on average), greater than that afforded with 16D3 
(−39.8% on average), and slightly lower of that induced 
by bevacizumab (−62.4% on average), when compared to 
vehicle and CP.
Collectively, these data demonstrated that iVR1 is 
a potent anti-tumor and anti-angiogenic molecule, with 
an efficacy similar to that displayed by bevacizumab and 
greater than that of mAbs anti-PlGF assayed.
Figure 2: iVR1 inhibited growth and neo-angiogenesis of syngenic and xenograft colorectal tumors. CT26 mouse colon 
carcinoma cells (A) or HCT-116 human colorectal cancer cells (C) were injected subcutaneously in Balb/c mice or CD1 nude athymic 
mice, respectively. iVR1 and control peptide (CP) were delivered at 50 mg/kg each other day. Anti-PlGF mAbs 5D11D4 (mouse) and 16D3 
(human) were delivered at 25 mg/kg twice a week. Bevacizumab (bevaciz) was delivered at 5 mg/kg, twice a week. Vehicle was PEG400/
water 1:1. TV was measured three times a week and data are represented as the mean ± SEM (N = 7). A, *p < 0.001 and §p < 0.0001 versus 
vehicle and CP; ^p < 0.02 and ¶p < 0.05 vs 5D11D4; #p < 0.002 versus vehicle and CP. C, §p < 0.01 and *p = 0.0001 versus vehicle and 
CP, ¶p < 0.05 versus 16D3; #p = 0.0027 versus vehicle and CP. Vessel density of syngenic (B) and xenograft (D) tumors, were calculated 
analyzing five optical fields for each tumor, counting CD31-positive vessels (brown). Data are represented as the mean ± SEM. B, * 
p < 0.007 versus vehicle and CP. D, §p < 0.005, #p < 0.02, and *p < 0.0005, versus vehicle and CP. ¶p < 0.05 bevaciz versus iVR1 and CP 
and iVR1 versus 16D3. (E) Representative pictures of CD31 staining (brown) of HCT-116 tumors. Scale bar, 100 μm.
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iVR1 is a potent inhibitor of monocyte-
macrophages and mural cells recruitment
Monocytes-macrophages play a well-established 
role in tumor angiogenesis [30, 31], and VEGFR1 has an 
active role for their recruitment at neo-angiogenic sites. We 
thereby determined the extent of monocytes-macrophages 
infiltration in tumors by F4/80 immunohistochemical 
analysis. In syngenic tumors, mAb 5D11D4 determined 
a significant reduction of F4/80 positive area compared 
to vehicle and CP (−52.7% on average), as expected by 
blocking one of theVEGFR1 specific ligands. The block 
of all the VEGFR1 ligands by iVR1 determined a greater 
reduction of F4/80 positive area compared to vehicle 
and CP (−78.0% on average). Such reduction was also 
significantly higher compared to 5D11D4 (−53.6%) 
(Figure 3A). In tumor xenografts, iVR1 treatment induced 
an impressive suppression of monocyte-macrophages 
recruitment compared to vehicle and CP (−81.3% on 
average). The inhibition resulted considerably higher 
compared to that produced by bevacizumab or 16D3 
treatments, which, however, also induced a substantial 
inhibition with respect to vehicle and CP (−67.6% and 
−49.4%, on average) (Figure 3B, 3C).
VEGFR1 has also a functional role in the 
recruitment of mural cells, a step required for maturation 
and stabilization of neovessels [19]. The extent of vessel 
coverage by smooth muscle cells in tumor xenografts 
was estimated by immunostaining with anti-smooth 
muscle α-actin (SMA). All the treatments determined 
significant and extensive reduction of vessel coverage, 
similar for 16D3 and iVR1 (−59.3% and −58.0% 
on average, respectively) and slightly lower for 
bevacizumab (−51% on average) compared to vehicle 
and CP (Figure 4A, 4B).
VEGFR1 phosphorylation status was evaluated in 
tumor xenograft protein extracts. Matching amounts of 
protein extracts from tumors belonging to the same group 
were mixed and analyzed by western blot. The block 
of single ligands, achieved with bevacizumab or 16D3, 
determined a partial decrease of VEGFR1 phosphorylation 
(−35.2% and −22.6% on average, respectively) compared 
to vehicle and CP, which were both ineffective. iVR1 
induced a powerful lessening of VEGFR1 phosphorylation 
(−78.2% on average, versus vehicle and CP)(Figure 4C).
Collectively, these data demonstrated that iVR1 is 
a potent inhibitor of VEGFR1 activation in vivo and of 
VEGFR1-mediated recruitment of non-endothelial cells 
involved in tumor angiogenesis.
iVR1 inhibited cell migration and tumor 
xenografts growth in a dose-dependent manner
The in vivo effects of iVR1 on cell recruitment were 
confirmed in vitro by inhibition of VEGF-A and PlGF-
induced migration of murine RAW 247.6 macrophages 
and ex vivo isolated peritoneal macrophages. Growth 
factors stimulated to similar extents cell migration, which 
was inhibited by iVR1 in a dose-dependent manner 
already at 10 μg/ml (Figure 5A, 5B).
In the attempt to optimize the dosage of iVR1, we 
treated mice bearing xenograft tumors with decreasing 
doses of compound (25 mg/kg and 10 mg/kg), while 
control mice were treated with vehicle and CP or 
bevacizumab at the dosages previously used (Figure 5C). 
iVR1 at 25 mg/kg still inhibited tumor growth as much as 
bevacizumab, while at 10 mg/kg no significant inhibition 
was observed. In subsequent experiments iVR1 thereby 
was delivered at 25 mg/kg.
iVR1 and irinotecan synergistically inhibited 
CRC in vivo growth
Among systemic treatments clinically approved 
for mCRC patients, irinotecan and bevacizumab 
containing regimens are largely used for their efficacy. 
Therefore, we evaluated if iVR1 activity might synergize 
with irinotecan, a camptotecin-based inhibitor of 
topoisomerase I [32]. Drugs were delivered starting 
at day 5 from cells inoculation and the combination 
treatment was compared to single treatments or vehicle 
(Figure 6A). At day 21 from cell inoculation, tumor 
growth inhibition induced by iVR1 was similar to that 
induced by irinotecan and both were significantly greater 
compared to vehicle (−58.3%, p < 0.005). Strikingly, the 
iVR1-irinotecan combination induced a very powerful 
inhibition of tumor growth already at day 21 (−82.1%, 
p < 0.0001 versus vehicle and −58.2%, p < 0.005, 
versus iVR1 and irinotecan alone), causing a progressive 
reduction of the tumors volume starting at day 16. Since 
we observed an almost total regression of tumors in the 
combination group, treatments were stopped seven days 
later. Indeed, at day 28, only two out of seven tumors 
were still detectable and for the next 20 days tumors were 
not measurable, with a delay in tumor relapse of about 50 
days compared to vehicle-treated tumors. iVR1-treated 
tumors relapsed more rapidly than the irinotecan-treated 
ones, both reaching 1500 – 1600 mm3 average volume 
20 and 30 days later, respectively, than vehicle-treated 
tumors (Figure 6A).
Therefore, we evaluated the inhibition of VEGFR1 
phosphorylation after delivery of iVR1 at 25 mg/kg. 
While irinotecan, as expected, did not affect VEGFR1 
phosphorylation, in iVR1 and iVR1 plus irinotecan-
treated tumors, a potent inhibition of VEGFR1 was 
observed. Inhibition was equivalent to that achieved 
delivering iVR1 at 50 mg/kg, thus indicating that even at 
25 mg/kg iVR1 affords a powerful anti-VEGFR1 activity 
in vivo (Figure 6B).
In order to evaluate the impact of treatments on 
the survival rate of tumor-bearing mice, and to compare 
the effect of iVR1-irinotecan combination with that 
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of bevacizumab-irinotecan, we performed a further 
experiment in which animals were treated with vehicle, 
irinotecan, iVR1, bevacizumab, iVR1-irinotecan and 
bevacizumab-irinotecan. Drugs were delivered, as for 
previous experiment, for 24 days starting from day 5 from 
cell inoculation and animals were sacrificed when tumors 
reached a volume close to 2000 mm3. Kaplan-Meier 
distribution is reported in Figure 6C. Treatments with 
bevacizumab, irinotecan or iVR1 likewise determined 
a median increase of survival comprised between 20 
and 28 days, compared to vehicle-treated mice. Again, 
the combination iVR1-irinotecan confirmed its synergic 
effect showing an activity fully comparable to that of 
the bevacizumab-irinotecan combination with a survival 
median increase of more than 40 days, compared to 
vehicle-treated mice.
Remarkably, no apparent signs of toxicity were 
observable after delivering iVR1 at 50 mg/kg for 14 days 
and at 25 mg/kg for 80 days, administered each other day. 
Also, body weight was recorded and no differences were 
observable in iVR1 treated mice as compared to vehicle or 
other controls (data not shown).
Collectively, these data confirmed the powerful 
therapeutic potential of iVR1 alone and in combination 
with irinotecan, which resulted comparable to that of 
bevacizumab alone or in combination regimen.
iVR1 prevented the development of CRC lung 
metastases in mice
VEGFR1 positive hematopoietic progenitors have 
been involved in metastatization process [22]. We thus 
investigated the effect of iVR1 in an artificial model of 
metastatization. HCT-116 cells were injected in the tail 
vein of nude mice and treatments with bevacizumab, 
iVR1, CP or vehicle (N = 5 per group) started immediately 
after cell injection, following the same schedule adopted 
for the combination and survival experiments. DNA 
was extracted from mice lungs to quantify human Alu 
sequences by qRT-PCR (Table 1 and Supplementary 
Figure 1). Alu sequences were well detectable at similar 
levels in the lungs of vehicle and CP treated mice. 
Bevacizumab induced a strong reduction compared to 
vehicle and CP whereas in iVR1-treated mice the quantity 
Figure 3: iVR1 inhibited the recruitment of monocyte-macrophages in syngenic and xenograft colorectal tumors. The 
area of monocyte-macrophage infiltrate in syngenic (A) and xenograft (B) tumors was determined by immunostaining with anti-F4/80 
antibody and calculated on five optical fields for each tumor. Data are represented as the mean ± SEM (N = 7). A, *p < 0.0005 and  
§p < 0.01 versus vehicle and CP; #p < 0.002 versus 5D11D4 . B, *p < 0.0005, §p < 0.005 and #p < 0.05, versus vehicle and CP; #p < 0.05 
versus bevacizumab (bevaciz); §p < 0.005 versus 16D3 (anti human PlGF mAb). (C) Representative pictures of F4/80 staining (brown) of 
HCT-116 tumors. Scale bar, 100 μm.
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of Alu sequences was barely detectable, suggesting that 
iVR1 was also active in preventing the transmigration of 
colorectal cancer cells from blood circulation to lung.
DISCUSSION
The role of VEGFR1 in pathological angiogenesis 
and its participation to the angiogenic switch and 
metastatic process are still under debate [3, 21, 22, 33]. 
We report a potent anti-tumor, anti-angiogenic and anti-
metastatic activity of the antagonist iVR1, which supports 
the important role played by VEGFR1 in tumor and, more 
in general, in pathological angiogenesis.
Among the several non-protein VEGFR1 antagonists 
so far described [23, 25–27, 34, 35] those with proven 
in vivo tumor inhibition activity are a ribozyme, the 
DNAzyme DT-18, the hexapeptide GNQWFI and the 
20-aminoacid peptide named BP-1 [23, 25–27]. None of 
these molecules have been so far tested in combination 
with chemotherapeutics nor assessment of survival rate has 
been reported. Therefore, iVR1 is the first VEGFR1 non-
protein antagonist for which extensive characterization as 
anti-tumor agent is reported and is also the first showing 
potent inhibition of VEGFR1 phosphorylation in vivo. 
This property, together with the effects observed on tumor 
vascularization, on inflammatory cells infiltration and on 
vessel stabilization, suggests the following considerations. 
The partial inhibition of VEGFR1 activation observed with 
mAbs anti-PlGF had the lowest effect on tumor growth and 
neoangiogenesis inhibition, as expected by the selective 
blockade of the PlGF/VEGFR1 axis. A similar reduction 
of VEGFR1 phosphorylation induced by bevacizumab, 
but associated with the inhibition of VEGFR2 activation 
through the blockade of VEGF-A, determined a much 
stronger decrease of tumor growth, neovascularization, 
and monocyte macrophage recruitment. Interestingly, the 
nearly fully block of VEGFR1 activation promoted by 
iVR1 translated into effects similar to those produced by 
bevacizumab, at least in terms of tumor growth and mural 
cells recruitment. Of note, while bevacizumab caused the 
highest reduction of neovessel formation, iVR1 determined 
the highest reduction of monocyte-macrophages infiltration. 
We hypothesize that the strong inhibition of monocyte-
macrophage recruitment at neo-angiogenic site, where they 
sustain and fuel pathological angiogenesis [30, 31], together 
with the potential inhibiting effects on the recruitment of 
others VEGFR1-positive bone marrow derived precursors, 
seemingly compensate for the lower effect on neovessel 
formation, as compared to bevacizumab activity.
Another potent VEGFR1 inhibitor is the mAb 
IMC-18F1 (icrucumab, Eli Lilly and Company), which in 
preclinical models of breast cancer inhibits tumor xenograft 
Figure 4: iVR1 inhibited the recruitment of smooth muscle cells in xenograft colorectal tumors blocking VEGFR1 
activation. (A) Smooth muscle α-actin (SMA)-positive vessels were counted on five optical fields for each tumor to quantify density of 
vessels covered by SMCs. *p < 0.020 and §p < 0.05 versus vehicle and CP. (B) Representative pictures of SMA staining (brown) of HCT-116 
tumors. Scale bar, 100 μm. (C) Top, western blot analysis of VEGFR1 phosphorylation performed on mixed matching amounts of protein 
extracts belonging to the same experimental tumor group. Low, normalization with anti-VEGFR1 antibody performed on the same filter. 
The values of densitometry analyses are shown. Values (in percentages) were calculated as the ratio of degree of receptor phosphorylation 
with respect to the total receptor amounts. The value of 100 has been arbitrarily assigned to vehicle.
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growth and synergizes with different chemotherapeutics, 
including cyclophosphamide or doxorubicin [16, 24]. 
IMC-18F1 is currently in phase 2 of clinical trials, for 
unresectable locally advanced or metastatic breast cancer 
in combination with capecitabine (http://clinicaltrials.
gov identifier NCT01234402), and as second-line therapy 
in combination with docetaxel, for locally advanced or 
metastatic transitional cell carcinoma of the bladder, urethra, 
ureter, or renal pelvis (http://clinicaltrials.gov identifier 
NCT01282463). Interestingly, preclinical studies showed 
that when used in combination with the mAb IMC-MF1, 
specific for mouse VEGFR1, IMC-18F1 enhanced the anti-
Figure 5: Dose-dependent inhibition of macrophage migration and xenograft tumor growth exerted by iVR1. iVR1, 
but not CP, was able to inhibit migration of mouse RAW264.7 macrophages (A) and ex vivo peritoneal macrophages (B) stimulated by 
VEGF-A or PlGF, in a dose-dependent manner. Data are expressed as fold induction with respect to vehicle (DMSO). A, *p < 0.0005 and 
§p < 0.001 versus CP and VEGF-A or PlGF. B, *p < 0.0005 and §p < 0.05 versus CP. (C) Dose-dependent inhibition of HCT-116 tumor 
growth exerted by iVR1 delivered at 10 or 25 mg/kg each other day. Bevacizumab (bevaciz) was delivered at 5 mg/kg two times at week. 
N = 7, *p < 0.001 versus vehicle and CP.
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Figure 6: iVR1 showed a synergic effect in combination with irinotecan. (A), iVR1 (25 mg/kg, each other day) and irinotecan 
(50 mg/kg once at week) were delivered alone or in combination starting at day 5 from cell inoculation and for 24 days. TV was measured 
three times a week and data are represented as the mean ± SEM (N = 7). At day 21: *p < 0.005 for iVR1 and irinotecan compared to vehicle, 
§p < 0.0001 versus vehicle, #p < 0.005 vs iVR1 and irinotecan. (B), top, western blot analysis of VEGFR1 phosphorylation performed on 
mixed matching amounts of protein extracts belonging to the same experimental tumor group. Low, normalization with anti-VEGFR1 
antibody performed on the same filter. The values of densitometry analyses are shown. Values (in percentages) were calculated as the 
ratio of degree of receptor phosphorylation with respect to the total receptor amounts. The value of 100 has been arbitrarily assigned to 
vehicle. (C), Kaplan-Meier survival curves of iVR1, irinorecan and bevacizumab (bevaciz, 5 mg/Kg two times a week) treatments, alone 
or in combination. Drugs were delivered as in A. Dashed line indicates 50% of survival. Bevaciz, irinotecan or iVR1 treatments were 
significantly lower compared to vehicle (p < 0.01) as well as the two combination treatments, iVR1 plus irinotecan and bevaciz plus 
irinotecan (p < 0.001).
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tumor efficacy [24]. These findings clearly indicated the 
relevance of blocking either human VEGFR1, expressed by 
tumor cells, and mouse VEGFR1, expressed on endogenous 
cells, which both contribute to tumor formation. In this 
regard, a major feature of iVR1 accounting for the potent 
activity showed in xenograft models is the ability to inhibit 
both human and mouse VEGFR1.
Differently from the current anti-angiogenic drugs 
(bevacizumab, aflibercept and TK inhibitors) used to 
treat cancer patients, iVR1 does not interfere with the 
VEGFA/VEGFR2 pathway. Although it is widely accepted 
that the blockade of VEGFA/VEGFR2 is crucial for 
inhibiting neovessel formation, mainly for the direct 
effects on endothelial cells, the impressive anti-tumor 
activity achieved with the irinotecan-iVR1 combination in 
CRC models, and the resulting outstanding survival rate 
comparable to that of irinotecan-bevacizumab combination, 
strengthen the concept that a potent and selective VEGFR1 
inhibition produces therapeutic effects comparable to 
those caused by the blockade of VEGF-A. This is probably 
mainly due to the potent inhibition of the recruitment of 
non-endothelial VEGFR1 positive cells involved in neo-
vessels formation. Moreover, VEGFR1 blockade may be 
advantageous in terms of toxicity. As indeed previously 
reported, blocking VEGFR1 or its specific ligand PlGF 
is less detrimental compared to VEGF-A blockade [36, 
37], which, given the vital role of VEGF-A/VEGFR2 
pathway in the physiological homeostasis of vessels [38], 
is responsible of the several side effects observed not only 
in cancer, but also in ocular neovascular diseases [6, 7].
Concerning the anti-metastatic activity of iVR1, this 
is in line with that exerted by the other VEGFR1 inhibitors 
previously mentioned, the ribozyme, the hexapeptide 
GNQWFI [23, 25], and the peptide BP-1 [26]. Based 
on our data, we hypothesize that the ability to prevent 
the activation and migration of VEGFR1 positive bone 
marrow precursors necessary for pre-metastatic niche 
formation [22], might represent one of the mechanisms by 
which iVR1 is able to fully prevent the transmigration of 
cancer cell from blood circulation to the lungs.
iVR1 is also able to potently reduce laser-induced 
CNV, the pre-clinical model for the age-related macular 
degeneration (AMD) condition. AMD is a VEGF-A-driven 
disease and currently patients are treated with ranibizumab 
or aflibercept, approved by FDA, or with bevacizumab off 
label [39]. Therefore, the anti-angiogenic activity of iVR1 
may be also explored in different pathological contexts 
where angiogenesis is involved.
Altogether, our results strongly support the concept 
that targeting VEGFR1 with selective inhibitors has a 
huge therapeutic potential in cancer, and more in general, 
in angiogenesis-driven diseases. Despite the micromolar 
affinity for VEGFR1, the outstanding anti-angiogenic 
properties, the anti-tumor features similar to those of 
bevacizumab, especially when it is used in combination 
with chemotherapeutics, and the preliminary observations 
supportive of a seemingly very low toxicity, makes 
iVR1 a very good candidate for further development. 
Further assessment of toxicity, drug metabolism and 
pharmacokinetics will be undertaken together with 
chemical modifications to improve potency, solubility and 
eventually absorption and distribution, to further improve 
the therapeutic index of this very promising compound.
MATERIALS AND METHODS
iVR1 peptide preparation
iVR1 and control peptides were synthesized as 
previously described [28]. For the in vivo delivery, we 
used as vehicle 50% polyethylene glycol (PEG) 400, 50% 
sterile water. Two hours before injection, peptides were 
Table 1: Quantification of human Alu sequences in DNA extracted from mice lungs
Standard curve Sample analysis
Human genomic DNA 
[ng]
CTm ± SD Sample CTm ± SD ng
200 19.02 ± 0.45 Vehicle 19.99 ± 0.20 121.87 ± 1.22
20 22.67 ± 0.83 CP 19.70 ± 0.36 145.91 ± 2.67
2 26.37 ± 0.52 bevaciz 22.68 ± 0.04 22.93* ± 0.04
0.2 29.75 ± 085 iVR1 30.05 ± 0.87 0.24* ± 0.01
0.02 33.99 ± 1.03    
Standard concentrations of human genomic DNA were used as template for qRT-PCR to amplify Alu sequences. For each 
concentration analyzed, the average values of cycle threshold (CTm) ± SD are reported (each point in triplicate) and a standard 
curve was constructed. Genomic DNA extracted from lungs of mice treated with vehicle, iVR1, CP and bevacizumab (bevaciz) 
(N = 5 per group) were amplified (see Supplementary Figure 1). Based on the average value of cycle threshold (CTm) obtained, 
the quantity of human Alu sequences were extrapolated by comparison with the standard curve, using exponential regression.
*p < 0.0001 versus vehicle and CP.
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suspended in PEG400/water by magnetic stirring at 50°C 
in sterilized glass vials. We obtained a stable and high 
homogeneous suspension containing up to 20 mg/ml of 
peptides.
Cell culture
CT26 (murine colon carcinoma), RAW 246.7 
(murine macrophage) and HCT-116 (human colorectal 
carcinoma) cell lines, all from American Type Culture 
Collection, were grown in RPMI 1640, DMEM and 
McCoy’s medium (Euroclone) respectively, supplemented 
with 10% inactivated Fetal Bovine Serum, 2 mM 
glutamine and standard concentration of antibiotics. 
Mouse macrophages were isolated from peritoneum of 
C57BL/6J mice by intraperitoneal injection of 1 mL of 3% 
Brewer thioglycollate Medium (Sigma). After 4 days mice 
were sacrificed and peritoneal lavage with cold-ice D-PBS 
20% FBS were performed to recover macrophages, which 
were stained with biotinylated rat anti mouse F4/80 (1:50; 
Serotec) and isolated using anti-biotin MicroBeads and 
MS Separation columns (Miltenyi Biotec).
Cell migration
Ex vivo isolated macrophages or starved RAW246.7 
cells (40000 cells/well) were placed into the upper 
chamber of a 24-multiwell insert system with 5-μm pore 
size polycarbonate filter (Corning). Cell migration was 
stimulated with VEGF-A or PLGF-1 (100 ng/mL) added to 
the starvation medium into the lower chamber, in presence 
of iVR1 (2 μM, 10 μM or 50 μM) or CP (50 μM). After 
24 h for RAW246.7, or 6 h for peritoneal macrophage, 
cells on the top of the filter were removed and those on 
the bottom side were stained with DAPI. Images were 
recorded on Leica DMI 6000 microscope equipped with 
Hamamatsu Orca R2 camera. Single cells were counted 
using Tile Scan Macro of LAS AF Software (Leica).
Animals
Balb/c mice or CD1 nude athymic mice, were 
purchased from Charles River. C57Bl/6J mice were 
purchased from The Jackson Laboratory. Animal 
experiments were in accordance with European directives 
no. 2010/63/UE and with Italian directives D.L. 26/2014, 
and with the guidelines of the University of Kentucky 
Institutional Animal Care and Use Committee. For all 
procedures, anesthesia was performed by intraperitoneal 
injection of 100 mg/kg ketamine hydrochloride and 10 
mg/kg xylazine.
Syngeneic and xenograft tumor models
7- to 8-week-old male Balb/c mice for syngeneic 
tumors model, or CD1 nude athymic mice for xenografts 
tumor model, were injected subcutaneously with 1 x 
106 CT26 or 4 x 106 HCT-116 cells into the right flank, 
respectively. Tumor volume (mm3) was quantified three 
times a week by measuring tumor shortest (d) and longest 
(D) diameters with an electronic caliper, using the formula 
D x d2/2. For all experiments, when tumors became 
measurable (by day 6 or 7 from cells injection, 50–100 
mm3) mice were randomly divided (n = 7). Treatments 
were performed by intraperitoneal injections (max volume 
100 μl) with the following schedules: vehicle PEG400/
H
2
O 1:1, iVR1, 10 to 50 mg/kg and control peptide 
(CP), 50 mg/kg, each other day; monoclonal antibodies 
anti-PlGF 5D11D4 and 16D3 (Thrombogenics), 25 mg/
kg, or bevacizumab (Genentech), 5 mg/kg, twice a week; 
irinotecan 50 mg/kg once a week. Mice weight was 
recorded at each tumor measurement. For ethical reasons, 
mice were sacrificed when tumor reached a volume 
between 1500 and 2000 mm3. The highest dose of iVR1 
at 50 mg/kg was chosen on the basis of the estimated IC
50
 
of 6–10 μM [28].
Artificial metastasis assay and quantification of 
human Alu sequences
7- to 8-week-old male CD1 nude athymic mice were 
anesthetized and injected with 3 x 105 HCT-116 cells via 
tail vein. Treatments by day zero and for 24 days, were 
performed with vehicle, CP and iVR1 (50 mg/kg), or 
bevacizumab, following the schedule reported before. 
Mice were sacrificed on day 25 and genomic DNA was 
extracted from all the lobes of mice lungs using QIAamp 
DNA Mini Kit (Qiagen). The concentration of double-
stranded DNA was determined using BIORAD Experion 
and 1K Experion DNA Kit (Biorad). To quantify human 
Alu sequences in DNA extracted from mice lungs, specific 
primers reported by Schneider et al. [40] were used to 
perform qRT-PCR as previously described [41].
Tumor protein extracts and western blot analysis
Frozen tumor samples were disrupted with a Tissue-
Lyser (Qiagen), 100 mg in 300 μL of lysis buffer (10 mM 
Tris-HCl pH 8, 150 mM NaCl, 1% Triton-X 100, 0.1% 
SDS, 0.5% Na-Deossycolate, 0.2% NaN
3
) supplemented 
with protease inhibitors (Roche), for 5 minutes at 3000 
rpm. The supernatants were recovered and stored at 
−80°C. Western blot analyses on mixed matching amounts 
of extracts belonging to the same experimental tumor 
group were performed as previously described [42].
Immunohistochemical analyses
10 μm-thick cryiopreserved tumors sections were 
fixed with PFA 4% and incubated overnight at 4°C 
with the following primary antibodies: rat anti-mouse 
PECAM-1 (anti-CD31; 1:1000; BD Pharmingen), rat 
anti-mouse F4/80 (1:50; Serotec) and anti-mouse smooth 
muscle α-actin (1:1000; DAKO). The staining procedure 
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was continued using specific secondary biotinylated 
antibody (all from DAKO). Slides were counterstained 
with hematoxylin. Images were recorded with a digital 
camera Leica. Densitometric analyses were performed 
with QwinPro software (Leica). Quantifications were 
performed on five optical fields for each tumor.
Choroid neo-vascularization
Laser photocoagulation procedure and CNV 
volumes determination were performed as previously 
described [43]. Immediately after laser application, 10 μg 
(4.2 nmol) and 50 μg (21 nmol) of iVR1 or 50μg of CP, 
in 1 μl of vehicle (DMSO), were injected intravitreally 
with a 33-gauge Exmire microsyringe (Ito Corporation) 
(N = 4 per group). As control, 2 ng of polyclonal anti-
mouse VEGF-A antibody (R&D Systems) in 1 μl PBS 
were injected.
Statistical analysis
Results are expressed as mean ± standard error of the 
mean (SEM), with P values < 0.05 considered statistically 
significant. Differences among groups were compared by 
the Student’s t test (two-tailed) or 1-way ANOVA. Tukey 
HD test was used as a post hoc test to identify which group 
differences account for the significant overall ANOVA. Log-
rank test was performed for Kaplan-Meier survival curves 
statistical analysis. All calculations were carried out using 
SPSS statistical package (vers14.1; SPSS, Inc., Chicago, IL).
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